HDAC6 and hepatocellular carcinoma: The participation of HDAC10 in the HCV life cycle was previously unknown; however, an important consequence of the simultaneous inhibition of HDAC6 and HDAC10 by tubastatin A is the preservation of the antiviral activity of the drug during the conversion from RP to PS hepatoma cells.